## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A		Reporting Perso	n*					ame and T <u>INC.</u> [ (			adin	g Symbol				ationship of all applical	•	•		
(Last)	(First	t)	(Middle	e)			te of E 9/201		ansacti	tion (	(Mon	th/Day/Year	)			Director Officer (g below)	ive title	X		Owner r (specify v)
575 HIGH S (Street)	TREET, S	SUITE 201				4. If A	mend	ment, Dat	e of O	Drigin	al Fi	led (Month/E	Day/Yea	ar)	6. Indi Line)	vidual or Jo Form fileo				
PALO ALT	O CA		9430	1	_										x	Form filed Person	-		-	
(City)	(Sta	-	(Zip)	No. D									6		G - : - II	0				
1. Title of Sec	urity (Instr		ne i -	2. Transa Date (Month/I	action	2/ E: r) if	A. Deer xecutic any		3. Tran Code 8)	sact	ion	4. Securitie Disposed ( 5)	es Acqu	ired (A	) or , 4 and	5. Amount Securities Beneficially Owned			nership Direct ct (I)	7. Nature of Indirect Beneficial Ownership
									Code	e	v	Amount	(A) (D)	or Pi	rice	Following Reported Transactior (Instr. 3 and		(Instr.		(Instr. 4)
Common Sto	ock			11/19	/2015				J <sup>(1)(</sup>	(2)		1,624,25	0 A	\$	0.00 <sup>(3)</sup>	6,457,56	54 <sup>(3)</sup>		I	See footnote <sup>(6</sup>
Common Sto	ock			11/19	/2015				J <sup>(1)(</sup>	(2)		19,059	A	\$	0.00(4)	75,781	(4)		I	See footnote <sup>(7</sup>
			Tal									osed of, o onvertible				ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	any	emed tion Date, if h/Day/Year)	4. Trans Code (Ir 8)		Deriva Acqui	mber of ative Securiti ired (A) or ised of (D) (I nd 5)	ies E	Expira	ation I	rcisable and Date y/Year)	Securit	and Amo ies Unde ive Secu		8. Price of Derivative Security (Instr. 5)	9. Num derivati Securiti Benefic Owned	ive ies cially	10. Ownershi Form: Direct (D) or Indirec	Beneficial Ownership
	Security				Code	v	(A)	(D)		Date Exerci	isable	Expiration Date	Title		Amount o Number o Shares		Followi Report Transad (Instr. 4	ed ction(s)	(I) (Instr. 4	4)
Warrant (right to buy) Warrant (right to	\$6.5 <sup>(1)</sup>	11/19/2015			J <sup>(1)(2)</sup>			389,290 <sup>(</sup>		(1	)	02/12/2016	Com Sto	ock	(3)(5)	\$0.00	98,84		I	See footnote <sup>(6)</sup> See
buy)	\$6.5 <sup>(1)</sup>	11/19/2015			J <sup>(1)(2)</sup>		<u> </u>	4,568 <sup>(4)</sup>	)(5)	(1	)	02/12/2016	Com		(4)(5)	\$0.00	1,16	50 <sup>(9)</sup>	I	footnote <sup>(7)</sup>
1. Name and A		Reporting Perso , LLC	n																	
(Last) 575 HIGH S	,	First) SUITE 201		(Middle)			-													
(Street) PALO ALT	о с	ČA		94301																
(City)	(5	State)		(Zip)																

(Last)	(First)	(Middle)	
575 HIGH STRE	. ,	(Middlo)	
(Street)			
PALO ALTO	CA	94301	
(City)	(State)	(Zip)	
( ),			
1. Name and Addre	ss of Reporting Pers		
1. Name and Addre			
1. Name and Addre	(First)	Fund, L.P.	
1. Name and Addre <u>Vivo Venture</u> (Last) 575 HIGH STRE	(First)	Fund, L.P.	
1. Name and Addre Vivo Venture (Last)	(First)	Fund, L.P.	

Explanation of Responses:

1. The warrant to purchase Common Stock is exercisable, at the holder's option, into shares of Capnia's Common Stock as follows: (i) at any time until the 15-month anniversary of the date of issuance, the holder is entitled to purchase one share of Capnia Common Stock at a cash exercise price equal to \$6.50 per share, or (ii) if, on any trading day after the four-month anniversary of the date of issuance of the warrant, and ending on the 15-month anniversary of the date of issuance of the warrant, the "market price" of a share of Capnia Common Stock is less than \$6.50, then the holder of the warrant may exercise the warrant in a cashless exercise to obtain a number of shares of Capnia Common Stock equal to: 125% of the difference between (a) the quotient of (i) the product of (A) the number of warrant shares being exercised

2. (Continued from Footnote 1) and (B) \$6.50, divided by (ii) 85% of the arithmetic average of the sum of the five lowest per share volume weighted average prices for the 15 trading days on the Nasdaq Capital Market (or if not on the Nasdaq Capital Market, on Capnia's then principal trading market) immediately prior to the date of exercise, and (b) the number of warrant shares being exercised. The five lowest per share volume weighted average prices for the 15 trading days on the Nasdaq Capital Market ranged from \$1.7228 to \$1.7882, inclusive. The reporting person undertakes to provide to Capina, any security holder of Capnia, or the staff of the Securities and Exchange Commission, upon request, full information regarding the five lowest per share volume weighted average prices for the 15 trading days on the Nasdaq Capital Market set forth in these Footnotes 1 and 2.

3. The holder cashless exercised the warrant for 1.624.250 shares of Common Stock as disclosed in Footnotes 1 and 2 in lieu of cash exercising the warrant for an aggregate of 389.290 shares at a cash exercise price per share of \$6.50.

4. The holder cashless exercised the warrant for 19,059 shares of Common Stock as disclosed in Footnotes 1 and 2 in lieu of cash exercising the warrant for an aggregate of 4,568 shares at a cash exercise price per share of \$6.50.

5. The shares of Common Stock reported in Column 5 and 7 are the number of shares of Common Stock issuable upon cash exercise of the warrant. The reporting person elected to cashless exercise the warrant. See Footnotes 1 and 2 regarding the calculation for determining the number of shares of Common Stock issued upon cashless exercise of the warrant

6. The shares are held directly by Vivo Ventures Fund V L.P. ("Vivo Ventures Fund V"). The Reporting Person is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such shares. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, M.D., Albert Cha, M.D., and certain other individuals are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein.

7. The shares are held directly by Vivo Ventures V Affiliates Fund L.P. ("Vivo Ventures V Affiliates Fund"). The Reporting Person is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. The Reporting Person is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such shares. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, M.D., and certain other individuals are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V except to the extent of any pecuniary interest therein.

8. The shares represented in Column 9 represent the number of shares issuable upon cash exercise of the warrant at \$6.50 per share following the cashless exercise of this warrant referenced in footnote 3.

9. The shares represented in Column 9 represent the number of shares issuable upon cash exercise of the warrant at \$6.50 per share following the cashless exercise of this warrant referenced in footnote 4.

## **Remarks:**

/s/ Edgar Engleman, a Manager of Vivo Ventures V, <u>11/23/2015</u> LLC /s/ Edgar Engleman, a Manager of Vivo Ventures V, 11/23/2015 LLC, the sole General Partner of Vivo Ventures Fund V, L.P. /s/ Edgar Engleman, a

Manager of Vivo Ventures V, 11/23/2015 LLC, the sole General Partner of Vivo Ventures V Affiliates Fund, L.P. Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.